ArticleJournal of clinical pharmacology2026

Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

Zoey Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.